恩扎鲁胺
抗雄激素
前列腺癌
医学
肿瘤科
内科学
非甾体
癌症
雄激素受体
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2019-08-01
卷期号:9 (8): OF7-OF7
标识
DOI:10.1158/2159-8290.cd-nb2019-066
摘要
Abstract According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI